SRC-Family Kinase and Macrophage Activation Inhibitors for Lupus Nephritis Identified by Single-Cell RNA Sequencing of Peripheral Blood Mononuclear Cells and Computational Drug Repurposing
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Lupus Nephritis (LN) is the most severe manifestation of Systemic Lupus Erythematosus, affecting approximately 50% of SLE patients with limited effective therapies. We applied a computational drug repurposing pipeline to single-cell RNA sequencing data from SLE/LN patient peripheral blood mononuclear cells (GSE135779; Arazi et al., Nature Immunology 2019; 84,000 cells; 12 clusters). Differential expression analysis of macrophage/monocyte clusters identified 6,956 LN-dysregulated genes, from which 125 ChEMBL-tractable targets were extracted spanning SRC-family kinases (HCK, LYN, FGR), macrophage activation markers (CD14, PLEK, RAC1), metabolic regulators (NAMPT, TKT), and lysosomal cathepsins (CTSB, CTSD, CTSS). Systematic screening of 12,459 unique compounds (pChEMBL >= 7.5) with USPTO prior art verification identified all 12,459 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (8 targets, score 88.5), DASATINIB (CHEMBL5416410, FDA-approved BCR-ABL/SRC inhibitor, 5 targets, score 59.5), PONATINIB (CHEMBL1171837, 4 targets, score 50.0), and CHEMBL3342183 (triple lysosomal cathepsin inhibitor CTSB/CTSD/CTSS, highest pChEMBL 10.96 in top 10, score 41.0). The SRC-family kinase triad HCK/LYN/FGR dominates the top 10 — appearing in 7 of 10 compounds across multiple chemically distinct scaffolds, providing strong biological validation of this axis. NAMPT (NAD+ biosynthesis rate-limiting enzyme) identified as a novel LN therapeutic target via CHEMBL5653589. DASATINIB achieves NOVEL_ALL USPTO status for lupus nephritis, providing a near-term repurposing opportunity with an established human safety profile. These findings are the basis of a filed USPTO provisional patent application (Ritschel Research, Micro-Entity, March 2026). Provisional patent specification: [add spec DOI after upload]. Pipeline code: https://github.com/glenritschel/lupus-nephritis-scrna
Fields of Study & Subjects
Systemic Lupus Erythematosus Research
Computational Drug Discovery Methods
Natural Compounds in Disease Treatment
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Preprint